Cipla shares fell sharply, dropping about 5 percent in trading following the release of the company’s third quarter financial results for fiscal 2026. The steep fall came after a 57 percent year-on-year decline in consolidated net profit to ₹676 crore, creating a disappointing moment for investors and dragging sentiment in the broader stock market. Strong…
On January 16, 2026, Cipla shares fell sharply as markets reacted to news that the company had temporarily stopped production of a key drug. The stock slid by around 4.5–5%, trading near its intraday lows on the BSE. This decline reflects rising investor concern about future revenue and supply disruption. What Happened at the Drug…
On Friday, September 26, 2025, Cipla shares fell 1.83%, making it one of the top losers on the Nifty 50. This decline follows recent fluctuations and highlights challenges in the pharmaceutical sector. Despite steady revenue and profit growth, Cipla’s stock has faced pressure. For June 2025, consolidated revenue rose to ₹6,957.47 crore from ₹6,693.94 crore…